During the last decades the parenteral iron supplementation has turned out to be effective and is the securest method of prophylaxis of the iron-deficiency anaemia in suckling piglets. The aim of this study was the comparison of two parenteral iron dextrane supplements of different producers, Ursoferran® 200 mg/ml pro inj. (Serumwerk Bernburg AG, Bernburg, Germany) and Medifer® 20 % (Medistar Arzneimittelvertrieb GmbH, Ascheberg, Germany) with regard to their therapeutically equivalence. Differences between the test groups related to average daily weight gain, clinical symptoms and general condition of the piglets were not significant. The evaluation of the injection sites with regard to histocompatibility showed no macroscopic modifications. The pathohistologic examination resulted in a lower score for tissue lesions for the group Ursoferran® 200 mg/ml pro inj.; as a matter of fact this supplement seemed to be better compatible. Haematocrit, number of erythrocytes and iron concentration were comparable in both groups and did not differ significantly. The thesis, storage capacity and utilization of iron competed with the ones of zinc and copper, could not be shown in the present study.
As a conclusion, Ursoferran® 200 mg/ml pro inj. as well as Medifer® 20 % had a positive influence on the growth performance of the piglets.
Ursoferran® 200 mg/ml pro inj. seemed to be resorbed faster and more effectively. With regard to haematological and clinical chemistry parameters both supplements showed a comparable effect. In the present study the equivalence of Ursoferran® 200 mg/ml pro inj. and Medifer® 20 % referring to efficiency and safety could be proven.
iron-deficiency anaemia / parenteral iron supplementation / piglet / Ursoferran® 200 mg/ml pro inj. / Medifer® 20 %